EFFECTIVENESS OF DOCETAXEL IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER IN THE FIRST TREATMENT LINE

被引：0
|
作者：
Villa, J. C. [1 ]
Espinosa, J. [1 ]
Gomez, R. [1 ]
Sanchez, V [1 ]
Lopez, R. [1 ]
Galan, R. [1 ]
Pineda, M. D. [1 ]
Perez, M. [1 ]
机构：
[1] Ciudad Real Univ Gen Hosp, Ciudad Real, Spain
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.236
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN8
引用
收藏
页码：A816 / A817
页数：2
相关论文
共 50 条
  • [31] Phospholipids as Indicators of Docetaxel-Resistant Castration-Resistant Prostate Cancer
    Ingram, Lishann M.
    Mansoura, Maryam
    Cummings, Brian S.
    FASEB JOURNAL, 2019, 33
  • [32] Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
    Mahon, K. L.
    Lin, H-M
    Castillo, L.
    Lee, B. Y.
    Lee-Ng, M.
    Chatfield, M. D.
    Chiam, K.
    Breit, S. N.
    Brown, D. A.
    Molloy, M. P.
    Marx, G. M.
    Pavlakis, N.
    Boyer, M. J.
    Stockler, M. R.
    Daly, R. J.
    Henshall, S. M.
    Horvath, G.
    BRITISH JOURNAL OF CANCER, 2015, 112 (08) : 1340 - 1348
  • [33] Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
    K L Mahon
    H-M Lin
    L Castillo
    B Y Lee
    M Lee-Ng
    M D Chatfield
    K Chiam
    S N Breit
    D A Brown
    M P Molloy
    G M Marx
    N Pavlakis
    M J Boyer
    M R Stockler
    R J Daly
    S M Henshall
    L G Horvath
    British Journal of Cancer, 2015, 112 : 1340 - 1348
  • [34] Enzalutamide in Castration-resistant Prostate Cancer Patients Progressing After Docetaxel and Abiraterone
    Schrader, Andres Jan
    Boegemann, Martin
    Ohlmann, Carsten-H.
    Schnoeller, Thomas J.
    Krabbe, Laura-Maria
    Hajili, Turkan
    Jentzmik, Florian
    Stoeckle, Michael
    Schrader, Mark
    Herrmann, Edwin
    Cronauer, Marcus V.
    EUROPEAN UROLOGY, 2014, 65 (01) : 30 - 36
  • [35] PREDICTION OF LEUKOPENIA AFTER DOCETAXEL CHEMOTHERAPY IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER
    Nakashima, Jun
    Takizawa, Issei
    Ko, Kazuyoshi
    Nakagami, Yoshihiro
    Ohori, Makoto
    Ohno, Yoshio
    Yoshioka, Kunihiko
    Tachibana, Masaaki
    JOURNAL OF UROLOGY, 2012, 187 (04): : E311 - E311
  • [36] A Phase I Study of Everolimus and Docetaxel in Patients With Castration-Resistant Prostate Cancer
    Courtney, Kevin D.
    Manola, Judith B.
    Elfiky, Aymen A.
    Ross, Robert
    Oh, William K.
    Yap, Jeffrey T.
    Van den Abbeele, Annick D.
    Ryan, Christopher W.
    Beer, Tomasz M.
    Loda, Massimo
    Priolo, Carmen
    Kantoff, Philip
    Taplin, Mary-Ellen
    CLINICAL GENITOURINARY CANCER, 2015, 13 (02) : 113 - 123
  • [37] PSA surge in patients with castration-resistant prostate cancer receiving docetaxel.
    Tabata, Ken-ichi
    Satoh, Takefumi
    Matsumoto, Kazumasa
    Fujita, Tetsuo
    Iwamura, Masatsugu
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [38] PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: Multicenter validation in patients from the Chinese Prostate Cancer Consortium
    Pei, Xinqi
    Wu, Kaijie
    Sun, Yinghao
    Xu Gao
    Gou, Xin
    Xu, Jun
    Gao, Fan
    He, Dalin
    Li, Lei
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (01) : 2.e11 - 2.e17
  • [39] Cost-effectiveness evaluation of abiraterone in the treatment of patients with castration-resistant prostate cancer who previously received docetaxel.
    Chopra, Akhil
    Gluck, Stefan
    Montero, Alberto J.
    Avancha, Kiran Kumar Venkata Raja
    Lopes, Gilberto
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [40] Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer
    Marin-Aguilera, Mercedes
    Codony-Servat, Jordi
    Kalko, Susana G.
    Fernandez, Pedro L.
    Bermudo, Raquel
    Buxo, Elvira
    Jose Ribal, Maria
    Gascon, Pedro
    Mellado, Begona
    MOLECULAR CANCER THERAPEUTICS, 2012, 11 (02) : 329 - 339
12345